<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to initial systemic therapy in patients with metastatic and recurrent squamous cell carcinoma of the head and neck</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to initial systemic therapy in patients with metastatic and recurrent squamous cell carcinoma of the head and neck</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to initial systemic therapy in patients with metastatic and recurrent squamous cell carcinoma of the head and neck</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Patients with advanced disease who are ineligible for or choose to forego salvage surgery and/or radiation therapy may be eligible for systemic therapy. The goals of treatment are palliative. The listed treatments are the preferred options, although alternative agents that are not listed may also be effective. Clinical trials are encouraged if available.</div><div class="graphic_footnotes"><p>PD-L1: programmed cell death ligand 1; CPS: combined positive score; ECOG: Eastern Cooperative Oncology Group.</p>
<p>* Systemic therapy may have been given with or without radiation therapy for initial management of locoregional disease.</p>
<p>¶ Progressive or recurrent disease within 6 months of receiving platinum-based chemotherapy with or without cetuximab.</p>
<p>Δ The benefit of pembrolizumab in patients with a CPS of less than 1 is limited. Patients who are not candidates for pembrolizumab may benefit from the addition of cetuximab to platinum-based chemotherapy. Platinum-based doublet chemotherapy alone may be preferred in patients with an impaired performance status.</p>
◊ Options for single-agent therapy include:
<ul>
<li>Platinum-based chemotherapy (carboplatin preferred)</li>
<li>Taxanes</li>
<li>Cetuximab</li>
<li>Fluorouracil</li>
<li>Methotrexate</li>
<li>Gemcitabine</li>
</ul>
<p class="extra_spacing">§ Eligibility for combination chemotherapy and/or immunotherapy is influenced by patient performance status, comorbidities, and prognostic factors. Combination chemotherapy is defined as doublet platinum-based chemotherapy.</p>
<p>¥ Alternatively, some UpToDate contributors substitute a taxane (paclitaxel or docetaxel) for the fluorouracil, based on better tolerability in other platinum-based combinations.</p>
‡ We prefer pembrolizumab with chemotherapy for patients with a good performance status (eg, ECOG performance status ≤2). For others, we prefer single-agent pembrolizumab.</div><div id="graphicVersion">Graphic 111698 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
